商用凝血活酶制剂中的血栓调节蛋白活性。

Thrombomodulin activity in commercial thromboplastin preparations.

作者信息

van Wijngaarden A, van den Besselaar A M, Bertina R M

出版信息

Thromb Res. 1986 Aug 1;43(3):265-74. doi: 10.1016/0049-3848(86)90146-5.

Abstract

Recently, it was reported that endothelial cells contain a membrane protein which serves as a cofactor for the activation of protein C by thrombin (thrombomodulin). Because many commercial thromboplastins are prepared from vessel-rich tissues/organs (lung, brain, placenta), it was hypothesized that some preparations may contain significant amounts of thrombomodulin; theoretically, thrombomodulin contaminations may enhance the prothrombin time. Among 8 different commercial thromboplastins tested two thromboplastins were found to contain significant amounts of thrombomodulin activity: Simplastin (64 U/ml) and Ortho (12.8 U/ml). However, we were unable to demonstrate that the presence of the thrombomodulin activity in these thromboplastins could affect the prothrombin time either by delaying fibrin formation (formation of thrombin-thrombomodulin complexes) or by inhibiting activated factor V (formation of activated protein C).

摘要

最近，有报道称内皮细胞含有一种膜蛋白，它作为凝血酶激活蛋白C的辅因子（血栓调节蛋白）。由于许多商业凝血活酶是从富含血管的组织/器官（肺、脑、胎盘）制备的，因此有人推测一些制剂可能含有大量的血栓调节蛋白；理论上，血栓调节蛋白污染可能会延长凝血酶原时间。在测试的8种不同商业凝血活酶中，发现两种凝血活酶含有大量的血栓调节蛋白活性：Simplastin（64 U/ml）和Ortho（12.8 U/ml）。然而，我们无法证明这些凝血活酶中血栓调节蛋白活性的存在会通过延迟纤维蛋白形成（凝血酶-血栓调节蛋白复合物的形成）或抑制活化因子V（活化蛋白C的形成）来影响凝血酶原时间。